NantHealth (NH) and Simulations Plus (SLP) Head to Head Survey

NantHealth (NASDAQ: NH) and Simulations Plus (NASDAQ:SLP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares NantHealth and Simulations Plus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NantHealth -225.76% -46.09% -25.23%
Simulations Plus 23.94% 23.95% 18.78%

Valuation and Earnings

This table compares NantHealth and Simulations Plus’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NantHealth $100.38 million 3.80 -$184.10 million ($1.78) -1.98
Simulations Plus $24.14 million 11.21 $5.78 million $0.33 47.43

Simulations Plus has lower revenue, but higher earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

7.1% of NantHealth shares are held by institutional investors. Comparatively, 33.6% of Simulations Plus shares are held by institutional investors. 58.0% of NantHealth shares are held by insiders. Comparatively, 36.9% of Simulations Plus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dividends

Simulations Plus pays an annual dividend of $0.24 per share and has a dividend yield of 1.5%. NantHealth does not pay a dividend. Simulations Plus pays out 72.7% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of recent ratings and target prices for NantHealth and Simulations Plus, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NantHealth 0 0 4 0 3.00
Simulations Plus 0 0 0 0 N/A

NantHealth currently has a consensus price target of $9.00, suggesting a potential upside of 155.68%. Given NantHealth’s higher probable upside, analysts plainly believe NantHealth is more favorable than Simulations Plus.

Volatility & Risk

NantHealth has a beta of -1.5, indicating that its stock price is 250% less volatile than the S&P 500. Comparatively, Simulations Plus has a beta of -0.76, indicating that its stock price is 176% less volatile than the S&P 500.

Summary

Simulations Plus beats NantHealth on 9 of the 14 factors compared between the two stocks.

NantHealth Company Profile

NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.

Simulations Plus Company Profile

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

What are top analysts saying about NantHealth? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NantHealth and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit